{"id":2778,"date":"2018-05-01T09:30:44","date_gmt":"2018-05-01T13:30:44","guid":{"rendered":"http:\/\/segoviaonlinedevelopment.ca\/clients\/Beta\/?page_id=2778"},"modified":"2022-05-17T12:33:52","modified_gmt":"2022-05-17T16:33:52","slug":"technology","status":"publish","type":"page","link":"http:\/\/segoviaonlinedevelopment.ca\/clients\/Beta\/technology\/","title":{"rendered":"The Technology"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.14.8″ background_color=”#0C71C3″ background_image=”http:\/\/segoviaonlinedevelopment.ca\/clients\/Beta\/wp-content\/uploads\/2022\/03\/bckgr_5.jpg” module_alignment=”center” max_height=”200px” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.14.8″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”center” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.14.8″ header_font=”Open Sans||||||||” header_text_color=”#ffffff” header_font_size=”38px” header_3_font=”|700|||||||” header_3_line_height=”1.3em” background_layout=”dark” custom_margin=”40px||40px||false|false” header_font_size_tablet=”30px” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

The Technology<\/span><\/h3>\n

MB-204<\/a> \u2022 Non-Hallucogenic Neuroplasticity Program<\/a><\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”MB-204″ module_id=”MB204″ _builder_version=”4.14.8″ _module_preset=”default” collapsed=”on” global_colors_info=”{}”][et_pb_row admin_label=”MB-204″ module_id=”MB204″ _builder_version=”4.14.8″ _module_preset=”default” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” header_3_text_color=”#0C71C3″ global_colors_info=”{}”]<\/p>\n

MB-204<\/h3>\n

[\/et_pb_text][et_pb_divider color=”#ffd800″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Marvel\u2019s lead compound (MB-204) is a novel fluorinated derivative of Istradefylline, the only clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson\u2019s disease.<\/p>\n

\"\"<\/p>\n

However, Marvel is developing MB-204 for diseases other than Parkinson\u2019s disease, specifically depression, Alzheimer\u2019s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Each disease area represents a multi-billion market with high, unmet medical need. By modifying a known approved drug with logical chemical changes, coupled with the potential to develop the drug for multiple unrelated diseases, Marvel believes it significantly de-risks its drug development efforts.<\/p>\n

\u00a0<\/h4>\n

Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases<\/span><\/h4>\n

Read full article here:<\/strong> https:\/\/pubmed.ncbi.nlm.nih.gov\/34635103\/<\/a><\/p>\n

\u00a0<\/h4>\n

CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease<\/h4>\n

Read full article here:<\/strong> https:\/\/pubmed.ncbi.nlm.nih.gov\/34033815\/<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” custom_margin=”40px||||false|false” global_colors_info=”{}”]<\/p>\n

Proposed Development Timeline:<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”TIMELINE” _builder_version=”4.14.8″ _module_preset=”default” collapsed=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Q2 : 2022″ _builder_version=”4.14.8″ _module_preset=”default” header_4_font=”|700|||||||” header_4_font_size=”20px” background_color=”#dddddd” height=”400px” height_tablet=”350px” height_phone=”400px” height_last_edited=”on|phone” custom_padding=”20px|20px|20px|20px|false|false” box_shadow_style=”preset2″ global_colors_info=”{}”]<\/p>\n

Q2:2022<\/strong><\/h4>\n

 <\/p>\n

Begin MB-204 4-week GLP toxicology studies<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Q3 : 2022″ _builder_version=”4.14.8″ _module_preset=”default” header_4_font=”|700|||||||” header_4_font_size=”20px” background_color=”#dddddd” height=”400px” height_tablet=”350px” height_phone=”400px” height_last_edited=”on|phone” custom_padding=”20px|20px|20px|20px|false|false” box_shadow_style=”preset2″ global_colors_info=”{}”]<\/p>\n

Q3:2022<\/strong><\/h4>\n

 <\/p>\n

Complete MB-204 GLP toxicology studies<\/p>\n

Complete cGMP Run of MB-204 API<\/p>\n

Complete cGMP finished product for trials<\/p>\n

FDA pre-IND meeting for MB-204<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Q4 : 2022″ _builder_version=”4.14.8″ _module_preset=”default” header_4_font=”|700|||||||” header_4_font_size=”20px” background_color=”#dddddd” height=”400px” height_tablet=”350px” height_phone=”400px” height_last_edited=”on|phone” custom_padding=”20px|20px|20px|20px|false|false” box_shadow_style=”preset2″ global_colors_info=”{}”]<\/p>\n

Q4:2022<\/strong><\/h4>\n

 <\/p>\n

Begin Phase 1\/2 clinical trial of MB-204<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Q1 : 2023″ _builder_version=”4.14.8″ _module_preset=”default” header_4_font=”|700|||||||” header_4_font_size=”20px” background_color=”#dddddd” height=”400px” height_tablet=”350px” height_phone=”400px” height_last_edited=”on|phone” custom_padding=”20px|20px|20px|20px|false|false” custom_padding_tablet=”20px|20px|20px|20px|false|false” custom_padding_phone=”20px||20px||false|false” custom_padding_last_edited=”on|phone” box_shadow_style=”preset2″ global_colors_info=”{}”]<\/p>\n

Q1:2023<\/strong><\/h4>\n

 <\/p>\n

Complete Phase 1\/2 clinical trial of MB- 204 includes placebo and efficacy endpoints<\/p>\n

Seek US exchange listing and partnership talks<\/p>\n

Comparable public companies at similar stage:<\/p>\n

Athira > $500M<\/strong>
Annovis > $250M<\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.14.8″ _module_preset=”default” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” text_font_size=”10px” text_line_height=”1.2em” global_colors_info=”{}”]<\/p>\n

*Note: timelines may be subject to change.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”NON-HALLUCINOGENIC” module_id=”nonhallucinogenic” _builder_version=”4.14.8″ _module_preset=”default” collapsed=”off” global_colors_info=”{}”][et_pb_row admin_label=”Non-Hallucinagenic” module_id=”nonhallucinogenic” _builder_version=”4.14.8″ _module_preset=”default” custom_padding=”||||false|false” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” text_text_color=”#0C71C3″ header_3_text_color=”#0C71C3″ global_colors_info=”{}”]<\/p>\n

Marvel Non-Hallucinogenic Neuroplasticity Program<\/h3>\n

[\/et_pb_text][et_pb_divider color=”#ffd800″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Marvel has identified a series of related compounds that appear to be potent, fast acting, water soluble and orally available small tryptamine derivatives that have anti-depressive activity but no overt hallucinatory activity in pilot studies.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”3_4,1_4″ admin_label=”Non-Hallucinogenic Block” _builder_version=”4.14.8″ _module_preset=”default” background_color=”#dddddd” custom_margin=”||100px||false|false” custom_padding=”40px|40px||40px|false|false” box_shadow_style=”preset2″ collapsed=”on” global_colors_info=”{}”][et_pb_column type=”3_4″ _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.14.8″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Second Program: Safer Neuroplastic Promoting Drugs<\/strong><\/h4>\n

 <\/p>\n

Marvel has identified a set of molecules inspired by the tryptamine class of psychedelics that are:<\/p>\n

 <\/p>\n